USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Novartis Pharma AG

USPTO PatentsView assignee record - 5 granted patents across 6 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

RSS updates for this company

The verdict

According to USPTO PatentsView, Novartis ranks #49,193 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 6 technology areas.

#49,193
of 49,997 US assignees by volume
12th percentile
by Innovation Score (23.3/100)
14.0
avg claims per patent
-75%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R49193 · Foreign Corporation #49,193 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #49,193/49,997
  • PHOTO-FINISH Nova Products
  • CPC-NARROW A61K · 6 areas
  • INNOV-THIN 23.3/100
  • CLAIMS-RICH 14.0 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DROP -75% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nova Products GmbH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Novartis’s 23.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Novartis

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Novartis's Innovation Score is 23.3/100 (12th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Novartis?

Each dot is one of Novartis’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Novartis’s own 14.0 claims/patent is at or below the 15.0 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Novartis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 4.95.05.055.05.05.1 01020304050 Granted patents (volume) Avg claims / patent Nova Products GmbH - 5, 10.6Nova ProductsNova Scientific, Inc. - 5, 45.6Nova ScientificNovahealth Biosystems, LLC - 5, 12.8Novahealth Biosys…Novares US Engine Components, Inc. - 5, 19Novares US Engine…Novartis Pharmaceuticals Corporation - 5, 11.4Novartis Pharmace…Novasep Process Solutions - 5, 17.4Novasep Process S…Novastone Media Ltd. - 5, 15Novastone MediaNovia Products, LLC - 5, 31.4Novia ProductsNovartis Pharma AG - 5, 14Novartis Pharma
Novartis vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Novartis's grants concentrate

Novartis Pharma AG is a focused PatentsView assignee: 6 CPC subclasses with 80% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2016 (2 grants) versus a trough of 1 in 2020. By volume, Novartis sits between Nova Products GmbH and Novia Products, LLC.

Who files at Novartis's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Novartis holds 5 patents at rank #49,223, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Novartis

By rank, the assignees closest to #49,223 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Novartis's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Novartis, neither rank-band nor same-CPC leaders (those blocks stay above). In A61K (Preparations FOR Medical), Novartis ranks #4,709 of 7,163 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (23 here).

Novartis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

23 12th percentile higher than 12% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 201620182020 1
USPTO utility patent grants by year · 2016–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Novartis Pharma AG patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 40.0%
2018 2 40.0%
2020 1 20.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Novartis Pharma AG's patent record in context - here's where to go next.

  • Novartis Pharma AG's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 80% of its portfolio - see every assignee active in that class. Explore A61K
  • Ranked #49,193 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Novartis Pharma AG against Nova Products GmbH, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 23.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.